|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.380 USD | -1.37% |
|
+3.02% | +20.26% |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,384 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 45.17% | - | - |
| Enterprise Value (EV) 1 | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,465 | 2,203 | 1,758 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 50.1% | -10.61% | -20.2% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -3.64x | 15x | 12.7x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -7.67x | -206x | 5.08x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.7x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.56x | 3.28x | 2.76x |
| EV / Revenue | 13.5x | 7.9x | 4.99x | 4.58x | 1.88x | 3.68x | 3.03x | 2.03x |
| EV / EBITDA | -12x | -14.6x | -16.2x | -1,592x | 4.8x | -9.94x | 11.4x | 4.11x |
| EV / EBIT | -12x | -14.4x | -15.9x | -812x | 4.82x | -4.21x | 11.1x | 7.07x |
| EV / FCF | -14.7x | -13.1x | -17x | -38.9x | 4.76x | -102x | 9.17x | 5.62x |
| FCF Yield | -6.81% | -7.63% | -5.88% | -2.57% | 21% | -0.98% | 10.9% | 17.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.578 | 0.6269 | 0.7378 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 669.4 | 726.2 | 865.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -248.1 | 192.6 | 428.3 |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -585.5 | 198.8 | 248.7 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -641.1 | 140.9 | 193.6 |
| Net Debt 1 | -368.3 | - | 426.7 | 507.7 | - | 80.91 | -180.6 | -625.6 |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 9.380 | 9.380 | 9.380 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 254,163 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 26/02/24 | 24/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.69x | 3.73x | -10.07x | -.--% | 2.42B | |
| 20.83x | 6.36x | 13.92x | 1.53% | 55.27B | |
| 32.72x | 8.17x | 25.61x | 0.05% | 54.15B | |
| -18.34x | 4.38x | -7.67x | -.--% | 23.22B | |
| -41.75x | 13.26x | -39.07x | -.--% | 23.11B | |
| 25.44x | 5.01x | 13.23x | -.--% | 20.33B | |
| 24.96x | 4.84x | 15.73x | -.--% | 17.91B | |
| -612.56x | 37.5x | -1557.05x | -.--% | 15.76B | |
| 45.31x | 18.35x | 47.24x | 0.08% | 15B | |
| 17.3x | 5.01x | 11.68x | -.--% | 13.82B | |
| Average | -50.98x | 10.66x | -148.64x | 0.17% | 24.1B | |
| Weighted average by Cap. | -25.93x | 9.69x | -91.58x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
